Benzimidazole compounds and antiviral uses thereof

Details Benzimidazole compounds and antiviral uses thereof Benzimidazole compounds and antiviral uses thereof

2006-04-18

2006-04-18

Stockton, Laura L. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S394000, C514S316000, C514S322000, C514S338000, C514S307000, C514S310000, C514S211080, C514S211150, C514S219000, C514S234500, C514S254060, C540S575000, C540S603000, C544S139000, C544S360000, C544S370000, C546S199000, C546S273400, C546S145000, C546S148000, C546S187000, C548S305700

Reexamination Certificate

active

07030150

ABSTRACT:
The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.

REFERENCES:
patent: 3394141 (1968-07-01), Sparatore
patent: 4839374 (1989-06-01), Janssens et al.
patent: 5280030 (1994-01-01), Jegham et al.
patent: 5399580 (1995-03-01), Daluge
patent: 5545653 (1996-08-01), Miller et al.
patent: 5559256 (1996-09-01), Gordon et al.
patent: 5576322 (1996-11-01), Takase et al.
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 5891874 (1999-04-01), Colacino
patent: 5932571 (1999-08-01), Maynard et al.
patent: 6194406 (2001-02-01), Kane et al.
patent: 6423704 (2002-07-01), Maynard et al.
patent: 6448281 (2002-09-01), Beaulieu et al.
patent: 11 78 070 (1964-09-01), None
patent: 0 151 826 (1985-08-01), None
patent: 0 161 049 (1990-02-01), None
patent: 0 747 363 (1996-12-01), None
patent: 9-3065 (1997-07-01), None
patent: WO 93/14088 (1993-07-01), None
patent: WO 96/00730 (1996-01-01), None
patent: WO 96/40125 (1996-12-01), None
patent: WO 97/24119 (1997-07-01), None
patent: WO-97/30991 (1997-08-01), None
patent: WO 98/37072 (1998-08-01), None
patent: WO 99/44596 (1999-09-01), None
patent: WO 00/04900 (2000-02-01), None
patent: WO 01/00611 (2001-01-01), None
patent: WO 01/00612 (2001-01-01), None
patent: WO 01/00615 (2001-01-01), None
patent: WO 01/27090 (2001-04-01), None
CA Registry No. 152072-73-6, entry date into the Registry file Jan. 4, 1994.
CA Registry No. 152072-57-6, entry date into the Registy file Jan. 4, 1994.
Bobosik et al., Heterocycles (1993), 35(2), pp. 1067-1074.
Sturm et al., Journal of Chromatography (1988), 430(1), pp. 43-51.
Kuzmierkiewicz, CA 106:50163, 1987.
Layton et al., Journal of the Chemical Society [Section] C: Organic (1968), (5), pp. 611-614.
U.S. Appl. No. 60/216,084, filed Jul. 6, 2000.
Abman et al., 1988, “Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis”, J Pediatr. 113(5):826-30.
Carstensen, J., 1995, Drug Stability: Principles and Practice, 2nded., Marcel Dekker, NY, NY pp. 379-380.
Castellanos et al., 1985, “Nucleophlic substitution in quaternary salts of N,N′-linked biazoles and related systems”, J. of the Chem. Society, 1209-1215.
Collings et al., 1984, “Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes”, J Virol. 49(2):572-8.
Doud et al., 1992, “Respiratory syncytial virus pneumonia in a lung transplant recipient: case report”, J Heart Lung Transplant. 11(1 Pt 1):77-9.
During et al., 1989, “Controlled release of dopamine from a polymeric brain implant: in vivo characterization”, Ann Neurol. 25(4):351-6.
Falsey et al., 1991, “Noninfluenza respiratory virus infection in long-term care facilities”, Infect Control Hosp Epidemiol. 12(10):602-8.
Feigen et al., eds., 1987, Textbook of Pediat. Infect. Disease, WB Saunders, Philadelphia, pp. 1653-1675.
Goodson et al., 1984, “The Scope of Dental Therapy”, Med. Applications of Controlled Release, vol. 2, pp. 115-138.
Grey et al., 1980, “Outbreak of respiratory syncytial virus infection in the elderly”, Br Med J. 281(6250):1253-4.
Groothuis et al., 1988, Respiratory syncytial virus infection in children with bronchopulmonary dysplasia', Pediatrics. 82(2):199-203.
Hall et al., 1981, “Modes of Transmission of Respiratory Synctial Virus”, J. Pediatr. 99:101-103.
Hall et al., 1979, “Neonatal respiratory syncytial virus infection”, N Engl J Med. 300(8):393-6.
Hall CB, 1993, “Respiratory Syntial Virus: What we know now”, Contemp Pediatr. 10:92-110.
Harrison et al., 1965, “Nucleophilic substitution reactions of 2-chlorobenzimidazoles. Part II. Formation of benzimidazoine2-2thiones and related compounds”, J. of the Chem. Society 3132-3135.
Hemming et al., 1995, “Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections”, Clin Microbiol Rev.8(1):22-23.
Henderson et al., 1979, “Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children”, N Engl J Med. 300(10):530-4.
Hertz et al., 1989, “Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature”, Medicine(Baltimore). 68(5):269-81.
Hollinshead and Smith, “Effects of Certain Purines and Related Compounds on Virus Propagation”, Purines in Virus Chemotherapy 123:54-62, 1958.
Howard et al., 1989, Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg. 71(1):105-12.
Ishida et al., 1975, “Tris (benzimidazo)-1,3,5-triazine from the thermolysis of 2-aryloxybeznzimaidazoles”, Bulletin of Chem. Soc. Of Japan 48:956-959.
Johnson et al., 1999, “A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9”, J Infect Dis. Jul.; 180(1):35-40.
Johnson et al., 1997, “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory synctial virus”, J Infect Dis. 176(5):1215-24.
Langer and Peppas, 1983, J Macromol. Sci. Rev. Marcomol. Chem. 23:61.
Langer et al., 1990, “New methods of drug delivery”, Science. 249(4976):1527-33.
Levy et al., 1985, “Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate”, Science. 228(4696):190-2.
Lopez Bernstein et al., Liposomes in the Therapy of Infectious Diseases and Cancer, Lopez-Bernstein and Fidler eds, Liss, NY, pp. 353-465, pp. 317-327, 1989.
MacDonald et al., 1982, “Respiratory syncytial viral infection in infants with congenital heart disease”, N Engl J Med. 307(7):397-400.
Murphy et al., 1994, “An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines”, Virus Res. 32(1):13-36.
Navas et al., 1992, “Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada”, J Pediatr. 121(3):348-54.
Patterson et al., 1990, “Molecular mechanisms of action of ribavirin”, Rev Infect Dis. 12(6):1139-46.
Peigue-Lafeuille et al., 1990, “Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin”, Scand J Infect Dis. 22(1):87-9.
Pohl et al., 1992, “Respiratory syncytial virus infections in pediatric liver transplant recipients”, J Infect Dis. 165(1):166-9.
Prince et al., 1985, “Quantitative aspects of passive immunity of respiratory syncytial virus infection in infant cotton rats”, J Virol. Sep.; 55(3):517-20.
Pringle et al., 1985, “A survey of respiratory syncytial virus and parainfluenza virus type 3 neutralising and immunoprecipitating antibodies in relation to Paget disease”, J Med Virol. 17(4):377-86.
Roderick et al., 1972, “Bisbenzimidazoles. Potent Inhibitors of Rhi

Affiliated with

Also associated with

Rating

Benzimidazole compounds and antiviral uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazole compounds and antiviral uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole compounds and antiviral uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3573623